Literature DB >> 17023091

Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease.

Zsuzsanna Hartai1, Anna Juhász, Agnes Rimanóczy, Tamás Janáky, Teodóra Donkó, László Dux, Botond Penke, Gábor K Tóth, Zoltán Janka, János Kálmán.   

Abstract

Kynurenine aminotransferases (KAT I and KAT II) are responsible for the transamination of kynurenine (KYN) to form kynurenic acid (KYNA), an excitatory amino acid receptor antagonist. Since these members of the kynurenine pathway (KP) are proposed to be involved in the pathogenesis of Alzheimer's dementia (AD), the activities of these enzymes and the levels of these metabolites were measured in the plasma and red blood cells (RBCs) of AD and control subjects together with the inheritance of the apolipoprotein (APOE) epsilon4 allele. KYNA levels were significantly decreased both in the plasma and in the RBCs in AD, but the levels of KYN and the activities of KAT I and KAT II remained unchanged. No association has been found with the possession of the epsilon4 allele. These findings indicate an altered peripheral KP in AD regardless of the APOE status of the probands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023091     DOI: 10.1016/j.neuint.2006.08.012

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  47 in total

1.  Peripheral Tryptophan - Kynurenine Metabolism Associated with Metabolic Syndrome is Different in Parkinson's and Alzheimer's Diseases.

Authors:  Gregory Oxenkrug; Marieke van der Hart; Julien Roeser; Paul Summergrad
Journal:  Endocrinol Diabetes Metab J       Date:  2017-11-19

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

3.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

Review 4.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

5.  Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease.

Authors:  S Duleu; A Mangas; F Sevin; B Veyret; A Bessede; M Geffard
Journal:  Int J Alzheimers Dis       Date:  2010-03-15

Review 6.  Inflammation, depression and dementia: are they connected?

Authors:  Brian E Leonard
Journal:  Neurochem Res       Date:  2007-08-20       Impact factor: 3.996

7.  Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions.

Authors:  Marita C Barth; Neil Ahluwalia; Thomas J T Anderson; Gregory J Hardy; Sumita Sinha; Jose A Alvarez-Cardona; Ivy E Pruitt; Eugene P Rhee; Richard A Colvin; Robert E Gerszten
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

Review 8.  The potential role of kynurenines in Alzheimer's disease: pathomechanism and therapeutic possibilities by influencing the glutamate receptors.

Authors:  Zsófia Majláth; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2013-12-18       Impact factor: 3.575

Review 9.  Metabolic aspects of neuronal degeneration: From a NAD+ point of view.

Authors:  Yo Sasaki
Journal:  Neurosci Res       Date:  2018-07-10       Impact factor: 3.304

Review 10.  The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease.

Authors:  Marta Amaral; Tiago F Outeiro; Nigel S Scrutton; Flaviano Giorgini
Journal:  J Mol Med (Berl)       Date:  2013-05-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.